Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Colon Cancer
- Thoracic Oncology
- Neoadjuvant Therapy
- Head and Neck Oncology
- Adjuvant Therapy
- Immunology
- Pancreatic Cancer
- Brain and Spinal Cord Cancer
Abstract
Citation: Clin Oncol. 2016;1(1):1160.DOI: 10.25107/2474-1663.1160
Excellent Response to Dual Her2 Targeted Therapy in a Patient with Advanced Colorectal Cancer in Fourth Line of Treatment
Juárez A, Montero M, Llorente M, Gálvez E, Durán R and Llorca C
Department of Medical Oncology, Elda Hospital, Spain
Department of Pathological Anatomy, Elda Hospital, Spain
PDF Full Text Case Report | Open Access
Abstract:
Men 47 years old with staged IV colon cancer Ras wild type and her 23+, who had progressed to all approved treatments, get an spectacular response with dual her2 targeted Therapy without chemotherapy. This is the first case reported with this treatment, supporting the results of HERACLES study, as well as encouraging the development of phase III studies.
Keywords:
Colon cáncer; Her2; Trastuzumab; Lapatinib
Cite the Article:
Juárez A, Montero M, Llorente M, Gálvez E, Durán R, Llorca C. Excellent Response to Dual Her2 Targeted Therapy in a Patient with Advanced Colorectal Cancer in Fourth Line of Treatment. Clin Oncol. 2016;1: 1160.
Search Our Journal
Journal Indexed In
